| Population name | Fadista |
| Genome | GRCh38 |
| Consortium | Not specified |
| Super population | EUR |
| Population description | COVID-19 HGI A2 cohort |
| Population origin | Not specified |
| Case population size | 4336 |
| Control population size | 623902 |
| Comorbidities | None specified |
| Mean / median age | Not specified |
| Sex | Not specified |
| Severity | Severe |
| Sample source | Nasopharyngeal swab / Whole blood |
| Method | Mendelian randomization (MR) study for IPF causality in COVID-19. Genetic variants associated with IPF susceptibility from previous GWAS were used as instrumental variables on COVID-19 severity from the GWAS meta-analysis by the COVID-19 HGI |
| Bioinformatics | Two-sample MR analysis was performed using the random-effects inverse-variance weighted method implemented in the R (version 3.6.1) package MendelianRandomization (version 0.5.0). |
| Imputation details | An allele frequency of 0.001 and an imputation info score of 0.6 was applied to each study before meta-analysis according to COVID-19 HGI protocol |
| Limitations | 1) Variance explained by the use of non-MUC5B IPF genetic instruments, although within the range typical of complex traits 2) Selection bias may play a rold in the protective effect found from rs35705950 as (a) a patient group that is heavily enriched for the rs35705950 T undertaking strict self-isolation and/or (b) due to survival bias of the rs35705950 non-IPF risk allele carriers. 2) Increased sample sizes, both from the IPF or COVID-19 GWAS could also have narrowed the confidence interval |